Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity – Roger Li
Sam Chang engages with Roger Li to delve into the TAR-210 study, focusing on bladder-based intravesical therapy targeting FGFR3 in non-muscle invasive bladder cancer (NMIBC) patients. Dr. Li shares insights from the multi-site international study, highlighting the efficacy of Erdafitinib, particularly in patients with FGFR alterations. Despite the challenges with oral Erdafitinib’s toxicity, the…